Integra LifeSciences’ second quarter results reflected ongoing business challenges, as management attributed the quarter’s flat revenue to ongoing reimbursement pressures in certain product lines and challenging year-over-year comparisons, especially in the tissue reconstruction segment. CEO Stuart Essig highlighted that while the company achieved important operational milestones—including the relaunch of key products and improved supply reliability—margin compression stemmed from a mix of increased interest expenses and product mix shifts. CFO Lea Daniels Knight acknowledged that, “the quarter’s outperformance in adjusted EPS was largely driven by operational execution and favorable tariff dynamics,” but reiterated that the company is operating in a complex environment marked by reimbursement and competitive challenges.
Is now the time to buy IART? Find out in our full research report (it’s free for active Edge members).
Integra LifeSciences (IART) Q2 CY2026 Highlights:
- Revenue: $418.8 million vs analyst estimates of $417.7 million (flat year on year, in line)
- Adjusted EPS: $0.56 vs analyst estimates of $0.48 (15.8% beat)
- Adjusted EBITDA: $78.41 million vs analyst estimates of $73.52 million (18.7% margin, 6.7% beat)
- The company reconfirmed its revenue guidance for the full year of $1.67 billion at the midpoint
- Management reiterated its full-year Adjusted EPS guidance of $2.45 at the midpoint
- Operating Margin: 9.6%, up from 7.9% in the same quarter last year
- Organic Revenue was flat year on year (beat)
- Market Capitalization: $1.39 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Integra LifeSciences’s Q2 Earnings Call
- Anton Hsieh (BMO Capital Markets) asked why full-year EPS guidance was not raised despite the Q2 beat; CFO Lea Daniels Knight explained that tariff gains offset higher expected interest expense from refinancing, so operational headwinds are not anticipated.
- Izzy Karp (BTIG) questioned CEO Stuart Essig about his recent return to the CEO role; Essig emphasized no need for a strategic reset, instead focusing on improved execution and accountability within the leadership team.
- Ravi Misra (Truist Securities) asked about what would drive results to the high or low end of guidance; Daniels Knight pointed to supply reliability and seasonal demand as key swing factors, with cost savings and execution determining the outcome.
- Ross Osborn (Wells Fargo) inquired about current and future demand for Integra Skin; Daniels Knight cited sequential revenue growth and expects to build on this momentum, but flagged ongoing competition and prior year comparison challenges.
- Raymond Zhang (Bank of America) asked about the timing and impact of SurgiMend’s relaunch; Essig confirmed a disciplined Q4 launch with a controlled rollout, leveraging lessons from PriMatrix and emphasizing a gradual ramp toward historical performance.
Catalysts in Upcoming Quarters
In upcoming quarters, the StockStory team will closely monitor (1) the phased commercial relaunch of SurgiMend and early demand signals from both legacy and new customers, (2) the pace and sustainability of cost savings from the current transformation initiatives and their effect on margins, and (3) signs of supply chain stability and recovery in key product lines, especially in tissue reconstruction and neurosurgery. The completion of regulatory milestones for SurgiMend and DuraSorb will also be critical markers for future growth potential.
Integra LifeSciences currently trades at $17.88, down from $19.76 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).
High-Quality Stocks for All Market Conditions
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.
